Company intelligence / Profile preview
Desitin Arzneimittel
Hamburg, Hamburg, Germanydesitinpharma.com ↗
- Ownership
- Private
- Employees
- ~290
- Development stage
- Other
01
Overview
Desitin Arzneimittel is a fully integrated, independent German pharmaceutical company focused on CNS diseases, particularly epilepsy and Parkinson's disease, with a broad range of in-house and in-licensed commercialized products in Europe. It specializes in small molecule drugs and has in the past out-licensed late-stage assets (e.g., sulthiame for sleep apnea). Clinical pipeline includes mature and established best-in-class CNS therapeutics.
- Therapeutic areas
- PulmonologyRare DiseasesNeurologyPsychiatry
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
AFT Pharmaceuticals (Pascomer licensing)Apnimed/Shionogi (Sulthiame out-licensing for sleep apnea)
Beyond the preview
Go deeper on Desitin Arzneimittel.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Desitin Arzneimittel.